Two new breast cancer drugs approved

Two new medicines discovered for treating breast cancer have been given the green light for use by the National Health Service in Britain.

The National Institute for Health andcare approved Palbociclib and Ribociclib medications after the price negotiations for treatment broadcast Klan Kosova.

Research indicates that these two drugs slow advanced cancer for at least 10 months and may delay the need for chemotherapy.

About 8,000 people in England will have access to drug use.

There are about 45,000 new breast cancer diagnosiss in there every year.

Palbociclib had previously been rejected by the National Institute for Health in Britain because of its high cost.